Drug intelligence / Profile preview

DX-465

Development stage: Preclinical
Lead developer: DermaXon
Modality: Small Molecules

Overview

DX-465 is a small molecule drug developed by DermaXon for dermatological and musculoskeletal indications. Its primary development focus is on the treatment of keratosis and acne vulgaris. As of March 2025, the drug remains in preclinical development, with no reported clinical trial results or regulatory approvals. The precise mechanism of action and molecular targets have not been publicly disclosed[1][5].

Beyond the preview

Go deeper on DX-465.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-465.

Explore the full profile